KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Exchange Rate Effect (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Exchange Rate Effect for 8 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Exchange Rate Effect rose 66.99% year-over-year to -$5.7 million, compared with a TTM value of $34.9 million through Dec 2025, up 329.25%, and an annual FY2025 reading of $34.9 million, up 329.25% over the prior year.
  • Exchange Rate Effect was -$5.7 million for Q4 2025 at Alnylam Pharmaceuticals, down from -$927000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $27.5 million in Q2 2025 and bottomed at -$17.3 million in Q4 2024.
  • Average Exchange Rate Effect over 5 years is $482000.0, with a median of -$1.6 million recorded in 2022.
  • The sharpest move saw Exchange Rate Effect tumbled 2300.0% in 2024, then skyrocketed 981.6% in 2025.
  • Year by year, Exchange Rate Effect stood at -$3.0 million in 2021, then skyrocketed by 153.08% to $1.6 million in 2022, then skyrocketed by 573.07% to $10.9 million in 2023, then tumbled by 258.49% to -$17.3 million in 2024, then soared by 66.99% to -$5.7 million in 2025.
  • Business Quant data shows Exchange Rate Effect for ALNY at -$5.7 million in Q4 2025, -$927000.0 in Q3 2025, and $27.5 million in Q2 2025.